Calah Raab
Acute Care · Duarte, CANPI 1245941806
Payments from drug & device makers
Across 53 payments — averaging $47.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$302
- Pfizer$257
- Astellas Pharma US Inc$255
- Evofem Biosciences, Inc.$184
- Springworks Therapeutics, Inc.$145
- Phathom Pharmaceuticals, Inc.$125
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,21888%
- Education$30412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 4 | $302 |
| Pfizer | 3 | $257 |
| Astellas Pharma US Inc | 4 | $255 |
| Evofem Biosciences, Inc. | 2 | $184 |
| Springworks Therapeutics, Inc. | 1 | $145 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $118 |
| Neurocrine Biosciences, Inc. | 1 | $114 |
| Regeneron | 1 | $114 |
| Merck | 5 | $107 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Amarin Pharma, Inc. | 1 | $90 |
| Sobi, Inc | 2 | $64 |
| E.r. Squibb & Sons, L.L.C. | 1 | $62 |
| Genmab U.S., Inc. | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Incyte Corporation | 2 | $45 |
| Melinta Therapeutics, LLC | 2 | $41 |
| Seagen Inc. | 2 | $36 |
| Amgen | 2 | $32 |
| Genentech USA, Inc. | 1 | $30 |
| AstraZeneca | 1 | $27 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Bristol Myers Squibb | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,521 in reported general payments places this provider in the 85th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 21 | $618 |
| Acyclovir | 33 | $529 |
| Fluconazole | 16 | $488 |
| Levetiracetam | 17 | $324 |
| Levofloxacin | 26 | $164 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $159 |
| Ondansetron OdtOndansetron | 11 | $117 |
Paid to pharmacies, not to this prescriber.
Other acute care in Duarte
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.